Zai Lab Limited ADR (ZLAB)
NASDAQ: ZLABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 25.31 0.00%
ZLAB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.84B
- EPS (TTM)
- -$1.70
- Dividend yield
- None
- 52-week range
- 15.96 – 33.97
- Day range
- 24.84 – 25.45
- Volume / Avg
- 290.20K / 961.44K
- Beta
- —
- Shares outstanding
- 112.27M
- Next earnings
- Nov 5, 2026
52-week range
ZLAB stock today
Zai Lab (ZLAB) closed at $25.31 on Oct 7, down 1.06% (-$0.27), versus the S&P 500's 0.22% decline. Trading was light, with 290.20K shares changing hands, about 30% of the average daily volume. Shares are 25.5% below their 52-week high of $33.97, set on Oct 6, 2025 and 58.6% above the 52-week low of $15.96, in the middle of the past year's range.
ZLAB is up 43.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 23.0%. Zai Lab has posted a net loss over the last twelve months (EPS of -$1.70), so its P/E ratio is not meaningful. Zai Lab's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Zai Lab
Company profileZai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Ying Du Ph.D.
- Headquarters
- Pudong
- Employees
- 1,784
- IPO year
- 2017
- Website
- zailaboratory.com
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$33.14+30.94%
- Strong buy 2
- Buy 9
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
Zai Lab peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DYNDyne Therapeutics Inc. | 15.97 | +3.70% | $2.98B | vs ZLAB |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 7.43 | -5.35% | $2.75B | vs ZLAB |
| ELVNEnliven Therapeutics Inc. | 41.36 | -2.43% | $3.03B | vs ZLAB |
| ARQTArcutis Biotherapeutics Inc. | 24.17 | +1.05% | $3.04B | vs ZLAB |
| PGENPrecigen Inc. | 7.54 | -0.13% | $2.70B | vs ZLAB |
| RCUSArcus Biosciences Inc. | 24.52 | +0.99% | $3.08B | vs ZLAB |
| MBXMBX Biosciences Inc. | 54.54 | -4.18% | $2.63B | vs ZLAB |
| NAMSNewAmsterdam Pharma Company N.V. | 22.13 | -0.63% | $2.59B | vs ZLAB |
Indexes, lists and sector
Zai Lab stock FAQ
What is Zai Lab's stock price today?
ZLAB last traded at $25.31 as of Oct 7, 4:00 PM EDT, down 1.06% on the day. Prices are delayed at least 15 minutes.
When is Zai Lab's next earnings date?
Zai Lab is expected to report earnings on Thursday, November 5, 2026.
Who is Zai Lab's CEO?
Dr. Ying Du Ph.D. is the chief executive officer of Zai Lab Limited ADR, which has about 1,784 employees.
What is the ZLAB 52-week high?
The 52-week high for ZLAB is $33.97 and the 52-week low is $15.96. The stock is currently 25.5% below its high.